126 results about "Tumor Cell Migration" patented technology

A modified pectin consists essentially of neutral sugar sequences with a low degree of branching capable of preventing tumor cell migration and cell to cell and cell to substratum adhesion.

The invention relates to a tumor cell migration dynamics monitoring method based on a microfluidic chip. The method particularly aims at the process of tumor cells migrating and moving into three-dimensional substrates from two-dimensional planes, the microfluidic chip mainly consists of a cell inlet pool (1), a collagen inlet pool (2), a waste liquid pool (3), cell culture rooms (4) and cell migration rooms (5), wherein the cell inlet pool (1) is connected with the upper parts of the cell culture rooms (5), the waste liquid pool (3) is connected with the lower parts of the cell culture rooms (5), and one cell culture room is connected with three cell migration rooms. The tumor cell migration dynamics monitoring method based on the microfluidic chip has the characteristic that the real-time tracking on the cell movement can be realized, and meanwhile, the accurate positioning at the beginning of the cell movement can be realized.

The invention discloses application of HIP-55 protein to development of tumor inhibition drugs. DNA molecules encoding and interfering HIP-55 protein from expressing siRNA are inserted into an expression vector to obtain a recombinant vector; the amino acid sequence of the HIP-55 protein is a sequence II in a sequence table; the invention also provides application of HIP-55 protein or the recombinant vector containing the HIP-55 protein coding gene to preparation of products having the following functions of (1) promoting tumor cell migration and/or (2) promoting tumor cell invasion. Experiments prove that the HIP-55 protein gene is overexpressed in lung cancer cells to promote tumor formation, lung cancer cell migration and lung cancer cell invasion; therefore, the HIP-55 provides a new target for clinical diagnosis, treatment and development of new drugs and can be used for screening, developing and/or designing products for prevention and/or treatment of tumors.

The invention discloses RGD tetrapeptide modified beta-carboline acyl-tryptophan and discloses a preparation method, a nanostructure, an effect of resisting tumor cell adhesion, an effect of resisting tumor cell invasion, an effect of resisting tumor cell migration, an anti-rumor effect and an effect of inhibiting tumor transfer to lung. The invention discloses application thereof in medicine. The formula is as shown in the specification.

Provided are a novel Epidermal growth factor receptor variant-EGFRvA protein, a polynucleotide encoding the EGFRvA protein and a method of preparing the EGFRvA protein via recombination technology. Also provided is a uses of the polynucleotide encoding the EGFRvA protein. The EGFRvA protein has a function of promoting tumor cell invasion or promoting tumor cell migration.

The invention relates to a kueide mycin which is a novel derivative of geldanamycin. According to the anticancer activity experiment, kueide mycin has in both vitro and vivo antitumor activities. The kueide mycin has the in vitro activity characteristics of inhibiting tumor cell proliferation, inducing the tumor cell apoptosis, reducing related target proteins of Hsp 90 in the tumor cells, as well as inhibiting the tumor cell migration, and has in vivo antitumor activity characteristics of notably reducing poisonousness compared to the geldanamycin. The kueide mycin can obviously inhibit the growth of solid tumor of a nude mouse model of Human breast carcinoma xenografts after being injected in a peritoneal cavity and is expected to be developed into a clinical effective antitumor drug.

The invention relates to application of miR-125b in antineoplastics, and in particular relates to a structure and a method for inhibiting tumor cell migration, reducing the medicine resistance of tumor cells or inducing tumor apoptosis, application of the structure or miR-125b in preparing a medicine, and a medicine for treating cancers. The structure comprises nucleic acid molecules for encoding miR-125b, wherein miR-125b has a nucleotide sequence as shown in SEQ ID NO:1. By adopting the structure, the nucleic acid molecules for encoding miR-125b can be guided into tumor cells, and furthermore by expressing miR-125b in the tumor cells, the tumor cell migration can be effectively inhibited, tumor cell apoptosis can be induced, or the medicine resistance of tumor cells to medicines is reduced.

The invention discloses a polypeptide with specificity inhibiting HB-EGF promoting tumor cell migration and infiltration and belongs to the technical field of biological medicine. According to the polypeptide, heparin-binding epidermal growth factors (HB-EGF) serve as target molecules, by means of three rounds of screening of the phage display technology, the bioactive polypeptide TUZG7 is obtained through specificity elution with HB-EGF as the effective component and phages of the target molecules. The bioactive polypeptide TUZG7 remarkably inhibits migration, filtration and other processes promoted by ovarian cancer cells of HB-EGF. The polypeptide is short in sequence, is easy to synthesize, can achieve large-scale production, can inhibit the cancer promoting function of HB-EGF, has the potential in being used for preparing anti-cancer medicine, and has important application value in the aspect of anti-cancer medicine research and development.

The present invention discloses a shRNA inhibiting SRSF6 gene expression, and a lentivirus expression vector and a construction method thereof, wherein the shRNA sequence is F:5'-CCGGCGTACAGAATACAGGCTTATTCTCGAGAATAAGCCTGTATTCTGTACGTTTTTG-3' and R:5'-AATTCAAAAACGTACAGAATACAGGCTTATTCTCGAGAATAAGCCTGTATTCTGTACG-3'. According to the lentivirus expression vector, the shRNA is inserted into vector plasmid PLKO.1 to construct PLKO.1-SRSF6-shRNA, the PLKO.1-SRSF6-shRNA and packaging plasmids PSPAX2 and PMD2. G are transfected into HEK293T cells after vector sequencing verifying is correct to obtain a lentivirus suspension, the lentivirus suspension is used to infect colorectal cancer cells, and then puromycin is used to screen and verify whether the virus packaging is successful. According to the present invention, the Western Blot results verify that the expression level of SRSF6 can be significantly reduced; the proliferation ability and the migration invasion ability of the colorectal cancer cells can be significantly reduced; and the research on the effect of SRSF6 on tumor cell migration and invasion ability is firstly provided.

The invention belongs to the technical fields of biomedicine technology and nanomedicine, and discloses a tumor-targeted liposome drug delivery system with three drugs co-loaded. A multifunctional drug delivery system which actively targets tumors is prepared by the steps that cationic liposome is used as a basic carrier, anti-inflammatory drugs and anti-tumor drugs are loaded in the liposome at the same time, a transmembrane anti-inflammatory peptide is covalently linked to the surface of the liposome, and then the outer layer of the cationic liposome is coated with hyaluronic acid. The liposome simultaneously has the functions such as targeted accumulation and deep penetration of tumor tissue, specific recognition of tumor cells and efficient uptake of the tumor cells and interstitial cells thereof. The multifunctional liposome carrier can co-deliver the transmembrane anti-inflammatory peptide, the anti-inflammatory drugs and the anti-tumor drugs to the tumors, fully exerts the synergistic therapeutic effect of the combined drugs, blocks the key signaling pathways of excessive activation of the tumor cells and the interstitial cells, can reduce the level of inflammation and immunosuppression in the tumors, destroy tumor microenvironment, cuts off tumor cell migration pathways, and finally clears the tumor cells and tumor stem cells.

The invention discloses a siRNA capable of specifically inhibiting expression of an Eya2 gene as well as a recombinant vector and an application of siRNA in reversing drug resistance of ovarian cancer to paclitaxel and belongs to the technical field of molecular biology and biological medicine. The siRNA comprises a sense strand 5'-UAGUUCUACCAUUUCCUUGUA-3' and an antisense strand 5'-CAAGGAAAUGGUAGAACUAGU-3'. The siRNA can specifically and efficiently inhibit mRNA and protein expression of the Eya2 gene, reduce tumor cell proliferation, accelerate tumor cell apoptosis, reduce tumor cell migration and invasion ability and effectively reverse drug resistance of ovarian cancer cells to paclitaxel. The invention further provides the application of Eya2 siRNA and recombinant vector thereof in preparation of drugs for treating ovarian cancer, prostate cancer, breast cancer, adenocarcinoma cancer, squamous-cell carcinoma, urethra cancer and cervical cancer or reversing drug resistance of ovarian cancer.

The invention discloses a vertical multi-electrode impedance sensor for real-time monitoring of 3D tumor cell migration and a preparation method thereof. According to the invention, a vertical multi-electrode impedance chip is processed by using an MEMS process; 3D culturing is carried out on tumor cells having migration abilities; one pair of vertical multi-electrode impedance chips is inserted into a 3D tumor cell culture chamber; and with changing of the number of 3D tumor cells, the impedance values detected by the multi-electrode impedance chips also change. Because of the migration characteristics of tumor cells, the numbers of tumor cells at different spatial locations in the same culture chamber change with time. The vertical multi-electrode impedance chips can simultaneously monitor the impedance values of 16 different positions in the same culture chamber and a 3D cell impedance hotspot map is drawn based on the impedance value, so that the real-time monitoring of 3D tumor cell migration is realized.

The invention belongs to the field of medicine, and provides a hinokiflavone derivative WG020, a preparation method of the hinokiflavone derivative and application to melanoma resistance. Through a cell toxicity experiment (MTT method), Hoechst33258 dyeing experiments, melanoma cell clone formation combination reaction experiments, flow cytometry (FCM) melanoma cell apoptosis experiments, westernblot (WB) apoptosis mechanism analysis experiments, cycle arrest experiments and tumor cell migration inhibition experiments, the results show that the WG020 has good inhibition effects on the clone formation of the melanoma cells; in addition, the melanoma cells can be induced to generate apoptosis; through data, the melanoma influence by the WG020 occurs in the period S of the cell period; goodinhibition effects are achieved on the melanoma cell migration. Therefore the hinokiflavone derivative WG020 can be used as a lead compound for inventing the novel anti-melanoma medicine. A novel source is provided for searching for the anti-melanoma medicine.

The invention discloses a compound nanoscale drug delivery system and application thereof in gynecological tumor treatment. The compound nanoscale drug delivery system comprises (a) a paclitaxel and curcumin composition serving as an active component, (b) miRNA-HA serving as a targeted material, and (c) carboxylated magnetic mesoporous silica serving as a carrier. According to the compound nanoscale drug delivery system, the carboxylated magnetic mesoporous silica serves as the drug carrier, on one hand, a high drug encapsulation capacity is ensured, and on the other hand, modifiable sites areprovided for modification of functional groups; and through modification of the targeted material miRNA-HA, the tumor cell targeting capability and gynecological tumor cell targeted inhibition of thecarboxylated magnetic mesoporous silica nanoscale drug delivery system can be improved, and the inhibition rate of tumor cell migration and invasion is increased. The compound nanoscale drug deliverysystem is reasonable in method design and simple in preparation technology and thus has wide application prospects, and a foundation is also laid for design and development of corresponding drug delivery systems.

The invention relates to polyester-polyether temperature-sensitive gel with slow release of batimastat and a preparation method thereof. The polyester-polyether temperature-sensitive gel specificallyconsists of an amphipathy block copolymer, and medicines and a solvent of effective amounts, wherein the amphipathy block copolymer consists of polyethylene glycol as a hydrophilic block and polyesteras a lyophobic block in a ratio of 4wt%-40wt%; and the ratio of batimastat is 0.1wt%-10wt%. The gel preparation is capable of effectively slowly releasing batimastat for 1-6 weeks, is at a solution state at room temperature or lower, can be turned into a gel state at human body temperature, has syringeability, is capable of effectively inhibiting matrix metalloproteinase of tumor tissue togetherwith chemotherapeutic medicines through intratumoral or peritumoral injection or postoperative tumor cavity administration, and has the potential of preventing tumor cell migration.

The invention discloses siRNA capable of specially inhibiting expression of an LAMB1 gene, a recombinant vector of the siRNA and application of the siRNA in reversing ovarian cancer taxol resistance, and belongs to the technical field of molecular biology and biological medicine. The siRNA comprises a sense strand and an antisense strand, the sense strand is 5'-UGUUUGAAAGCCGAAUCUGCG-3', and the antisense strand is 5'-CAGAUUCGGCUUUCAAACAAA-3'. According to the siRNA, mRNA and protein expression of the LAMB1 gene in a cancer cell can be inhibited specially and efficiently, proliferation of the cancer cell is reduced, cell apoptosis is increased, the invasiveness and migration capability of the cancer cell is reduced, and moreover, the resistance of an ovarian cancer cell to taxol can be reversed effectively. The invention further provides the application of the siRNA and the recombinant vector thereof in preparing medicines treating an ovarian cancer, a hepatocellular cancer, a colorectal cancer, a malignant glioma, a prostatic cancer or a gastric cancer and medicines reversing the ovarian cancer taxol resistance.

The present application is directed to compositions and methods for treating a subject with cancer and/or increasing migration of a mesenchymal stromal cells (MSCs) stimulated with a recombinant autocrine motility factor (rAMF) to a tumor or a tumor cell, e.g. hepatocellular carcinoma (HCC). In addition, methods for increasing adhesion of MSCs to endothelial cells with rAMF are disclosed. In some embodiments, the MSCs comprise a therapeutic agent, e.g., an anti-tumor agent.

The invention relates to the fields of tumor molecular biology and tumor drug treatment. The invention provides a use of CD133 as a tumor cell invasion marker and an application with CD133 as a target for screening drugs that inhibit tumor cell invasion. According to the invention, technologies of plasmid transfection, rat glioma model establishment, vivo imaging, immunohistochemistry and Transwellare employed to verify the high expression of the CD133 in invasion foci around glioma, and it is verified that highly-expressed glioma cells are more susceptible to invasion in vivo and in vitro. Further research indicates thatthe CD133 makes glioma more susceptible to invasion by improving tumor cell migration capability and altering cytoskeletal. The CD133 can provide tumor treatment programme selection and antitumor drug screening with new ideas.

A treatment for cancer, and in particular, of therapeutic compounds which block the ability of cytokines and chemokines to promote metastasis of malignant cells. The therapeutic compound comprises a carboxylated and/or sulfated oligosaccharide, preferably in a substantially purified form, which is a heparin or heparan-sulfate derived saccharide compound. In one embodiment of the present invention, the carbohydrate or oligosaccharide has a molecular weight of no more than about 3000 daltons, preferably lying in the range of about 400 to about 2000 daltons, most preferably between about 400 and about 1100 daltons. Generally, substances of the present invention inhibit tumor cell migration, as determined by biological assays, and comprise molecules of various sugar units of which the basic unit of activity is associated with a disaccharide. However, larger oligosaccharide chains of up to about 10 sugar units, containing the basic disaccharide unit of activity can also function to inhibit such activity.

The invention discloses a micro-fluidic chip for analyzing and sorting tumor cell migration capability. The micro-fluidic chip comprises a cell sample introduction channel, a chemical concentration gradient channel, a migration channel and a micro hook; two branches of the cell sample introduction channel are connected with the chemical concentration gradient channel through the migration channel; the micro hook is arranged at the joint of the cell sample introduction channel and the migration channel; a cell sample introduction inlet is formed in the top end of the cell sample introduction channel; a compound sample introduction inlet is formed in the bottom end of the chemical concentration gradient channel; a cell sample introduction outlet is formed in the middle of the chemical concentration gradient channel; and a compound sample outlet is formed in the top end of the chemical concentration gradient channel. Data collection can be carried out on migration paths and migration forms of cells in real time, and the data are analyzed to obtain the migration capability of each cell, the individual difference between the migration capabilities and the ratio of strong/weak migration cell subgroups. In addition, cell subgroups with specific migration capabilities can be enriched by microfluidic operations respectively, for subsequent molecular biology inventions.